Alpha4beta7 integrin antagonists - Pipeline Insight, 2024

Alpha4beta7 integrin antagonists - Pipeline Insight, 2024

DelveInsight’s, “Alpha4beta7 integrin antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Alpha4beta7 integrin antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Alpha4beta7 integrin antagonists Understanding

Alpha4beta7 integrin antagonists: Overview

The integrin alpha4beta7, expressed on the surface of B and T lymphocytes, plays an essential role in lymphocyte trafficking throughout the gastrointestinal (GI) tract via interaction with its primary ligand, mucosal addressin cell adhesion molecule (MAdCAM). Elevated MAdCAM expression in the intestines and liver has been linked to GI-associated autoimmune disorders, including Crohn's disease, ulcerative colitis, and hepatitis C. Monoclonal antibodies that block the interaction of alpha4beta7 with MAdCAM inhibit lymphocyte homing to murine intestines without effecting migration to peripheral organs; this suggests that alpha4beta7-selective antagonists might be useful as GI specific antiinflammatory agents. Subsequent optimization of initial peptide leads afforded alpha4beta7-selective heptapeptide inhibitors that competitively inhibit binding to MAdCAM in vitro and inhibit lymphocyte homing to murine intestines in vivo.

""Alpha4beta7 integrin antagonists - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alpha4beta7 integrin antagonists pipeline landscape is provided which includes the disease overview and Alpha4beta7 integrin antagonists treatment guidelines. The assessment part of the report embraces, in depth Alpha4beta7 integrin antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alpha4beta7 integrin antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

● The companies and academics are working to assess challenges and seek opportunities that could influence Alpha4beta7 integrin antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Alpha4beta7 integrin antagonists.

Alpha4beta7 integrin antagonists Emerging Drugs Chapters

This segment of the Alpha4beta7 integrin antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Alpha4beta7 integrin antagonists Emerging Drugs

• Etrolizumab: Hoffman-La-Roche

Etrolizumab (rhuMAb Beta7) is the first dual-action anti-integrin antibody in Phase III trials designed to selectively control disease in the gut of patients with two major forms of inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn’s disease (CD). It is a humanized monoclonal antibody against the β7 subunit of integrins α4β7 and αEβ7. Etrolizumab was developed by Genentech by engineering the FIB504 antibody to include human IgG1-heavy chain and κ-light chain frameworks; it is manufactured in Chinese hamster ovary (CHO) cells. Etrolizumab with its dual mechanism of action can inhibit leucocyte trafficking to the gut (by blocking of α4β7- MAdCAM-1 interactions) and inhibit retention of leucocytes in the intraepithelial lining of the gut (by blocking αEβ7- E-cadherin interactions). This can potentially improve the efficacy and specificity for the treatment of UC. A multicenter, Phase III, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of etrolizumab compared with placebo during induction and maintenance treatment of moderately to severely active Crohn's Disease has been completed.

• PN-943: Protagonist Therapeutics

PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in clinical development for the treatment of inflammatory bowel disease. PN-943 is designed to offer the convenience of oral administration and the potential for improved safety and tolerability compared to antibody therapeutics administered by injection that target the alpha-4-beta-7 integrin pathway. PN-943 has completed Phase I development, demonstrating sustained target engagement with two weeks of daily administration. The drug is currently being evaluated in Phase II clinical trial to treat Ulcerative Colitis.

Further product details are provided in the report……..

Alpha4beta7 integrin antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Alpha4beta7 integrin antagonists drugs segregated based on following parameters that define the scope of the report, such as:

● Major Players in Alpha4beta7 integrin antagonists

There are approx. 7+ key companies which are developing the therapies for Alpha4beta7 integrin antagonists. The companies which have their Alpha4beta7 integrin antagonists drug candidates in the most advanced stage, i.e. phase III include Hoffman-La-Roche.

● Phases

DelveInsight’s report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration

Alpha4beta7 integrin antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular

● Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Polymer
• Small molecule

● Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Alpha4beta7 integrin antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha4beta7 integrin antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha4beta7 integrin antagonists drugs.

Alpha4beta7 integrin antagonists Report Insights

• Alpha4beta7 integrin antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Alpha4beta7 integrin antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Alpha4beta7 integrin antagonists drugs?
• How many Alpha4beta7 integrin antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alpha4beta7 integrin antagonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alpha4beta7 integrin antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Alpha4beta7 integrin antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?